Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Celyad and Medisun Alter Terms of China Stem Cell Deal

publication date: Aug 31, 2015
Celyad SA, a Belgium cell therapy company, announced an altered China collaboration with Medisun International of Hong Kong for greater China registration and distribution of  C-Cure®. C-Cure is a stem cell-based treatment for ischemic heart failure that was developed by Mayo Clinic and licensed by Celyad. Medisun agreed to invest at least $22 million to register the treatment in China. The agreement was originally announced one year ago; now, the two entities have altered its terms. More details....

Stock Symbol: (Euronext: CYAD)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here